141 related articles for article (PubMed ID: 11877286)
1. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
Baron F; Turhan AG; Giron-Michel J; Azzarone B; Bentires-Alj M; Bours V; Bourhis JH; Chouaib S; Caignard A
Blood; 2002 Mar; 99(6):2107-13. PubMed ID: 11877286
[TBL] [Abstract][Full Text] [Related]
2. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
[TBL] [Abstract][Full Text] [Related]
3. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
[TBL] [Abstract][Full Text] [Related]
5. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
6. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
[TBL] [Abstract][Full Text] [Related]
7. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7.
Issaad C; Ahmed M; Novault S; Bonnet ML; Bennardo T; Varet B; Vainchenker W; Turhan AG
Leukemia; 2000 Apr; 14(4):662-70. PubMed ID: 10764152
[TBL] [Abstract][Full Text] [Related]
8. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.
Miller JS; Verfaillie C; McGlave P
Blood; 1992 Nov; 80(9):2182-7. PubMed ID: 1384796
[TBL] [Abstract][Full Text] [Related]
9. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.
Holyoake TL; Jiang X; Jorgensen HG; Graham S; Alcorn MJ; Laird C; Eaves AC; Eaves CJ
Blood; 2001 Feb; 97(3):720-8. PubMed ID: 11157490
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
11. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
[TBL] [Abstract][Full Text] [Related]
12. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
13. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
14. KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.
Izumi K; Shindo T; Ngo HT; Nakayama-Hosoya K; Akahane K; Tamai M; Nguyen TTT; Kawana-Tachikawa A; Inukai T; Takaori-Kondo A
Immunohorizons; 2021 Aug; 5(8):687-702. PubMed ID: 34433624
[TBL] [Abstract][Full Text] [Related]
15. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells.
Jewett A; Wang MY; Teruel A; Poupak Z; Bostanian Z; Park NH
Hum Immunol; 2003 May; 64(5):505-20. PubMed ID: 12691701
[TBL] [Abstract][Full Text] [Related]
16. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
17. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Monteghirfo S; Tosetti F; Ambrosini C; Stigliani S; Pozzi S; Frassoni F; Fassina G; Soverini S; Albini A; Ferrari N
Mol Cancer Ther; 2008 Sep; 7(9):2692-702. PubMed ID: 18790751
[TBL] [Abstract][Full Text] [Related]
18. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
Reuther JY; Reuther GW; Cortez D; Pendergast AM; Baldwin AS
Genes Dev; 1998 Apr; 12(7):968-81. PubMed ID: 9531535
[TBL] [Abstract][Full Text] [Related]
19. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
20. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]